loader from loading.io
🧬 Silencing Risk: Lepodisiran vs Lp(a) show art 🧬 Silencing Risk: Lepodisiran vs Lp(a)

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

🚨 New hope for high Lp(a)! 💉 Lepodisiran, a long-acting siRNA, slashed Lp(a) by 94% with just 2 shots/year. 🔬 RNA precision meets cardiac prevention. 📉 Silent killer, silenced. #CardioTwitter #RNAtherapy #LipoproteinA

info_outline
💨 Breathing Battles: Navigating COPD Phenotypes show art 💨 Breathing Battles: Navigating COPD Phenotypes

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

🌬️🚶‍♂️ COPD comes in many forms! From chronic bronchitis 🪫 to emphysema 💨, frequent exacerbators 🚨, asthma-COPD overlap 🌪️, and eosinophilic type 🧫. Tailoring treatment to phenotype is key! #COPD #PrecisionMedicine #RespiratoryCare

info_outline
💊 TANDEM Triumph: Dual Power for LDL Cholesterol Reduction! show art 💊 TANDEM Triumph: Dual Power for LDL Cholesterol Reduction!

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

🚀 TANDEM Trial: Combining Obicetrapib & Ezetimibe for a powerful LDL reduction! 💊 ✅ -48.6% vs placebo, -27.9% vs Ezetimibe, -16.8% vs Obicetrapib 💪 Safe, effective, and oral! #Cardiology #LipidManagement #ASCVD

info_outline
Fungal Pharmacists, Fatty Liver, Future Frontiers 🧬🩸🍄 show art Fungal Pharmacists, Fatty Liver, Future Frontiers 🧬🩸🍄

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

A gut fungus 🍄 (Fusarium foetens) secretes FF-C1 🧪, a metabolite that inhibits CerS6 and lowers ceramides 🩸—shielding mice from MASH 🛡️. Fungi aren’t just freeloaders—they may be our next therapeutic allies! 💊🧠 #Microbiome #LiverHealth #FungalTherapy #Science

info_outline
💪 Powerful Cholesterol Control: Obicetrapib in the Spotlight 🌟 show art 💪 Powerful Cholesterol Control: Obicetrapib in the Spotlight 🌟

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

🚀 Obicetrapib: A Breakthrough in LDL Lowering! 📉 Reduced LDL by 29.9% in high-risk patients (p<0.001) 💡 Promising adjunct to lipid-lowering therapy! #Cardiology #LipidManagement #HeartHealth 💓

info_outline
Fat Chance! 🔬🧬 Middle-Age Spread Starts at the Cellular Level show art Fat Chance! 🔬🧬 Middle-Age Spread Starts at the Cellular Level

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

Here’s a tweet with emojis based on the article:   🧬 Middle-age spread decoded! 🕰️ Visceral fat grows in midlife not from bigger cells—but new ones! 🎯 CP-A cells fire up fat formation via LIFR–STAT3 🔥 💊 Targeting them may halt metabolic disease before it starts. #Aging #Obesity #CellBiology #Metabolism 🧫   Would you like a version with a more humorous tone or one tailored for clinicians?

info_outline
🔍📊🛡️ Detect, Decode, Defend: A New Era in Coronary Risk Prediction show art 🔍📊🛡️ Detect, Decode, Defend: A New Era in Coronary Risk Prediction

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

🚨 New era in heart disease prediction! 🧬 + 🧪 + 🤖 = Meta-prediction model that beats PCE & QRISK3 📈 Detects hidden CAD risk in young, women & “low-risk” groups 🎯 Precision prevention just got personal. 🫀 Published in Nature Medicine #CardioTwitter #AI #Genomics #CAD

info_outline
Dr RR Baliga's Philosophical Discourses: Epicurus (Greece, 341–270 BCE) – Founder of Epicureanism show art Dr RR Baliga's Philosophical Discourses: Epicurus (Greece, 341–270 BCE) – Founder of Epicureanism

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

Epicurus (341–270 BC) was an ancient Greek philosopher who founded Epicureanism, emphasizing the pursuit of a tranquil, happy life through ataraxia (freedom from fear) and aponia (absence of pain). His teachings combined atomism, ethics, and naturalistic theology, advocating simple living, friendship, and the rejection of superstition.

info_outline
Calcium Wars: Orbital Atherectomy vs. Balloon Angioplasty — The ECLIPSE Verdict ⚔️🧠💔 show art Calcium Wars: Orbital Atherectomy vs. Balloon Angioplasty — The ECLIPSE Verdict ⚔️🧠💔

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

🚨ECLIPSE Trial Results🚨 Orbital atherectomy 🌀 vs. balloon angioplasty 🎈 before stenting in severe coronary calcification 💔 🎯 No added benefit with atherectomy 🧠 Balloon-first + imaging = smart strategy 📊 Lancet 2025 | #CardioTwitter #InterventionalCardiology #ECLIPSETrial

info_outline
Genes 🧬, Journeys 🌍, and Hidden Hazards ⚡: Unlocking Health with Exposomics show art Genes 🧬, Journeys 🌍, and Hidden Hazards ⚡: Unlocking Health with Exposomics

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

  “Your DNA 🧬 is just half the story — your exposome 🌍 writes the rest! From air 🌫️ to food 🍎 to stress 😰, exposomics unlocks the hidden drivers of health 🔍💥. Predict. Prevent. Prosper. 🚀 #Exposomics #PrecisionMedicine”

info_outline
 
More Episodes

Coronary CT angiography-guided management of patients
with stable chest pain: 10-year outcomes from the SCOT-
HEART randomised controlled trial in Scotland


Michelle C Williams, Ryan Wereski, Christopher Tuck, Philip D Adamson, Anoop S V Shah, Edwin J R van Beek, Giles Roditi, Colin Berry,Nicholas Boon, Marcus Flather, Steff Lewis, John Norrie, Adam D Timmis, Nicholas L Mills, Marc R Dweck, David E Newby, on behalf of theSCOT-HEART Investigators*


Summary
Background The Scottish Computed Tomography of the Heart (SCOT-HEART) trial demonstrated that management
guided by coronary CT angiography (CCTA) improved the diagnosis, management, and outcome of patients with
stable chest pain. We aimed to assess whether CCTA-guided care results in sustained long-term improvements in
management and outcomes.


Methods SCOT-HEART was an open-label, multicentre, parallel group trial for which patients were recruited from
12 outpatient cardiology chest pain clinics across Scotland. Eligible patients were aged 18–75 years with symptoms of
suspected stable angina due to coronary heart disease. Patients were randomly assigned (1:1) to standard of care plus
CCTA or standard of care alone. In this prespecified 10-year analysis, prescribing data, coronary procedural
interventions, and clinical outcomes were obtained through record linkage from national registries. The primary
outcome was coronary heart disease death or non-fatal myocardial infarction on an intention-to-treat basis. This trial
is registered at ClinicalTrials.gov (NCT01149590) and is complete.


Findings Between Nov 18, 2010, and Sept 24, 2014, 4146 patients were recruited (mean age 57 years [SD 10], 2325 [56·1%] male, 1821 [43·9%] female), with 2073 randomly assigned to standard care and CCTA and 2073 to standard care
alone. After a median of 10·0 years (IQR 9·3–11·0), coronary heart disease death or non-fatal myocardial infarction
was less frequent in the CCTA group compared with the standard care group (137 [6·6%] vs 171 [8·2%]; hazard ratio
[HR] 0·79 [95% CI 0·63–0·99], p=0·044). Rates of all-cause, cardiovascular, and coronary heart disease death, and
non-fatal stroke, were similar between the groups (p>0·05 for all), but non-fatal myocardial infarctions (90 [4·3%] vs
124 [6·0%]; HR 0·72 [0·55–0·94], p=0·017) and major adverse cardiovascular events (172 [8·3%] vs 214 [10·3%];
HR 0·80 [0·65–0·97], p=0·026) were less frequent in the CCTA group. Rates of coronary revascularisation procedures
were similar (315 [15·2%] vs 318 [15·3%]; HR 1·00 [0·86–1·17], p=0·99) but preventive therapy prescribing remained
more frequent in the CCTA group (831 [55·9%] of 1486 vs 728 [49·0%] of 1485 patients with available data; odds ratio
1·17 [95% CI 1·01–1·36], p=0·034).


Interpretation After 10 years, CCTA-guided management of patients with stable chest pain was associated with a
sustained reduction in coronary heart disease death or non-fatal myocardial infarction. Identification of coronary
atherosclerosis by CCTA improves long-term cardiovascular disease prevention in patients with stable chest pain.